






          
 
   
  




Objective: to develop a population pharmacokinetic model taking into account blood losses during and after orthopedic surgery in adult 
hemophilia A patients receiving infusion of coagulation factor VIII, and to evaluate the influence of potential covariates. 
Methods: Factor VIII pharmacokinetic parameters were calculated from 24 patients. Among them, 7 were HIV+. The observations were analyzed 
with the mixed-effects compartment pharmacokinetic package NONMEM and the first-order conditional estimation method. To evaluate the 
stability and robustness of the final model the bootstrap method was used. 
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1) was related to body weight (P = 0.0263) and viral status (P = 
0.0078). Moreover, the peripheral volume of distribution was related to body weight (P=0.0362). In the final model, only the viral status was 
significant for V1 when compared with the base model. Posterior predictive checks and robustness analysis showed that the model adequately 
described the pharmacokinetic parameters. The HIV covariate accounted for 29.8% of the unexplained variation across patients for V1. V1 increased 
by 33.3% in HIV+ patients compared to HIV- patients. 
Conclusion: A population pharmacokinetic model taking into account blood losses during and after orthopedic surgery was developed. The 33.3% 
increase in V1
Keywords: Factor VIII, Population pharmacokinetics, Hemophilia A, Orthopedic surgery. 
 observed in HIV+ patients explained the need for higher doses in these patients. 
 
INTRODUCTION 
Hemophilia (A and B) is a recessively inherited bleeding disorder in 
which the blood does not clot normally. It is caused by a reduction in 
the amount or activity of factor VIII (FVIII-C; antihemophilic 
globulin), cofactor for factor IX in the activation of factor X in the 
coagulation cascade. The consequence is the formation of fibrin 
deficient clots which makes coagulation much more prolonged, and 
the clot more unstable. Hemophilia A is the most common form. In 
humans, factor VIII is encoded by the F8 gene [1,2]. 
Treatment of hemorrhage and prophylaxis against bleeding following 
surgery is based on the infusion of factor VIII. A guidance for the 
management of hemophilia A patients undergoing surgical procedures 
has been published [3]. Both frequent bolus injections, intermittent or 
continuous infusions have been used to keep adequate factor VIII 
levels [4]. Several studies have demonstrated that continuous 
infusions provide improved coagulation factor cover [5-9]. Moreover, 
this mode of administration may be a further means of reducing the 
consumption of factor VIII. The short half-life of factor VIII is the main 
obstacle in maintaining adequate blood levels. The use of 
pharmacokinetics is a valuable tool to achieve the optimal treatment 
for an individual patient [4,10]. Either non-compartmental or 
compartmental (one- or two-compartment models) approach has 
been used to estimate factor VIII pharmacokinetic parameters [1,11-
30]. In all of these studies, an important inter individual variability in 
pharmacokinetic parameters has been reported. The influence of age, 
body weight and plasma concentration of von Willebrand factor was 
investigated to explain this variability. A nomogram based on the 
factor VIII concentration measured at 10 h after preoperative loading 
dose has also been published to individualize factor VIII dosing 
requirements [31]. Bayesian estimates of the pharmacokinetic 
parameters have been reported [30-35]. In this study, a population 
pharmacokinetic model taking into account blood losses during and 
after orthopedic surgery was developed in adult patients with 
hemophilia A receiving a plasma-derived or recombinant factor VIII 
concentrate. The purpose was i) to determine accurate population 
pharmacokinetic parameters by using a two-compartmental open 
model, and ii) to accurately estimate both inter- and residual 
variability in pharmacokinetic parameters.  
MATERIALS AND METHODS 
Patients 
The retrospective study was conducted in collaboration with the 
Regional Center of Hemophilia, Lyon, France. The study proceeded 
within the framework of the clinical practice in accordance with 
institutional guidelines. 
Thirty Caucasian male hemophilia patients undergoing total knee 
prothesis were included. Mostly severe hemophilia patients over 18 
years old were included, only two patients had moderate 
hemophilia. Nine patients (30%) were HIV+. Their average CD4 cell 
count was 496 ± 202 cells/mm3and all of them had severe 
hemophilia. No patient had anti factor VIII antibodies detected and 
platelet counts were higher than 100x109
Patients were treated with a plasma-derived (factane) or 
recombinant factor VIII concentrate (Advate
 /L. Patients were from 25 
to 61 years old and their body weight ranged from 49 to 95 kg. 
Factor VIII baseline concentration ranged from 0.005to 0.09 IU/mL 
(mean ± SD, 0.019 ± 0.024 IU/mL). The duration of the surgery was 
from 60 to 240 minutes.  
®, Helivate®, ReFacto® 
or Kogenate®). Just before surgery (time 0), each patient received a 
loading dose of 25 to 103 IU/kg factor VIII, depending on the patient, 
administered by intravenous infusion over a 10-minute period 
followed by continuous infusions for at least one week. The total 
dose administered to the patients ranged from 314 to 962 IU/kg. 
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Sample collection and analytical method 
Blood samples were collected in citrate-coated polypropylene tubes 
immediately before factor VIII injection and at repeated intervals 
during the infusion (T1, T6, T24, T48, T72, T96, T120, T126, T143 
and T198 hours). The number of blood samples per patient ranged 
from 7 to 10. 
Factor VIII concentrations were measured using an optic detection 
of clotting. The assay was performed on a MDA II automate (Bio 
Merieux, France). The quantification limit was 0.5% (0.005 IU/mL). 
Precision was lower than 4% for factor VIII concentrations from 
0.027 to 1.18 IU/mL. 
Population pharmacokinetic analysis 
Factor VIII concentration versus time data were modeled using non-
linear mixed-effects modeling in NONMEM 7 (Globomax LLC, 
Hanover, Md, USA) [36]. Estimation of typical population 
pharmacokinetic parameters and random inter-individual variability 
(IIV) associated with observed and predicted concentrations were 
done using a first-order conditional estimation method with ε-η 
interaction (FOCE INTER) [36]. Model discrimination was based i) 
on graphical assessment of goodness-of-fit plots [i. e. measured 
concentrations (DV) versus population (PRED) and individual 
predictions (IPRED), weighted residuals (WRES)versus PRED, and 
WRES versus time], and ii) on the basis of changes in –2 log-
likelihood (OF). The difference in OFs between two hierarchical 
models was used as a likelihood ratio test statistic. This was 
approximately distributed as χ2 with the number of degrees of 
freedom equal to the difference in the number of parameters 
estimated between the two hierarchical models. Testing was 
performed at α level of 0.05. For nested models that differed by one 
parameter, a difference in OF of more than 3.84 favoured the model 
with more parameters. 
A two-compartmental model fitted data better than a one-
compartmental pharmacokinetic model. This model was 
parameterized in terms of central volume of distribution (V1), 

















compartmental clearance (Q).  
Two additional parameters, α and β, were added to the structural 
model to take into account blood losses during and after surgery, 
respectively. The following equations were used:  
 
where V0 is the baseline volume of distribution, Vols is the total 
blood volume estimated from weight and height [37], PCHI 
corresponds to blood loss during the surgery, and POST corresponds 
to the blood loss after the surgery. Blood losses were recorded 
manually in drains during and after surgery. IIV in pharmacokinetic 
parameters was assessed according to an exponential error model. 
ThePjparameter of the jth subject was described by the relationship: 
Pj = Pmean x exp(ηP) 
Where, Pj is the pharmacokinetic parameter of subject j, Pmean the 
population pharmacokinetic parameter, and ηP a Gaussian random 
variable with mean zero and variance of ω²ηP.
Out of 30 patients enrolled in the study, six were excluded. Four of 
them received packed red blood cells on 2 to 4 separate occasions 
over the 72 hours after surgery and two others were excluded for 
lacking information regarding blood losses. Thus, the 
pharmacokinetic model development data set consisted of 24 
patients and 205 factor VIII concentrations. Among them, 7 patients 
(29.2%) were HIV+.  
  
Table 1: It shows population pharmacokinetic parameters 
 The residual 
variability was estimated using a proportional error model. 
Importantly, the standard errors (SE) of these estimates were also 
obtained, providing a measure of goodness of fit for each parameter. 
The following covariates HIV status, age, body surface area, weight 
and height were available for inclusion in the final model. The 
covariate analysis was done by a forward inclusion procedure 
followed by a backward deletion step. Bothlinear functions, power 
models, and allometric scaling were tested (covariates being centred 
or not around the mean values). The effect of each covariate was 
assessed by the likelihood ratio test. 
Individual parameters were calculated as empirical Bayes estimates 
using the POSTHOC option in NONMEM. The terminal half-life was 
calculated from the individual primary pharmacokinetic parameters. 
Performance of the model 
The model’s performance was assessed by examining the prediction 
error (PE). PE was defined as [(DV-IPRED or PRED)/IPRED or PRED] 
x 100%. Both MDPE (median of all PEs) and MDAPE (median of all 
absolute PEs) were calculated.  
Using the final model, the visual predictive checks (VPCs) were 
carried out by simulating 1000 virtual data sets to assess the 
performance of the model.  
This analysis was performed using PsN [38] and Xpose [39]. The 5th, 
50th (population median response) and 95th percentile 
concentrations were plotted against time and the factor VIII 
concentrations were superimposed. 
Validation of the final model 
The bootstrap resampling procedure was used for evaluating the 
stability and robustness of the final model using PsN [40]. The 
bootstrap resampling was repeated 1000 times to evaluate whether 
an appreciable discrepancy existed between the parameter values 
estimated from the original data and the estimated bootstrap mean 
values. Final population parameters were compared with those 
obtained from the 1000 bootstrap analyses. 
RESULTS 
 Population parameters 
before covariate inclusion 
Population parameters 
after covariate inclusion 
 Mean (% RSE) IIV, % (% RSE) Mean (% RSE) IIV, % (% RSE) 
V1 = θ1 2650 (40.2)  (mL) 55.9 (63.6) - - 
V1 = θ1 x VIH status + θ - 7 - θ1 = 3020 (24.1) 
θ7 
46.8 (76.3) 
= −1940 (61.2) 
CL = θ2 (mL h-1 220 (5.8) ) 30.8 (38.6) 220 (5.9) 30.7 (38.6) 
V2 = θ3 2471 (29.1)  (mL) 79.2 (54.5) 2600 (28.1) 69.6 (60.4) 
Q = θ4 (mL h-1 615 (48.7) ) NE 616 (34.7) NE 
α = θ 901 (74.9) 5 - 1560 (70.9) - 
β = θ 1621 (40.8) 6 - 1740 (32.2) - 
Residual variability (%) 0.15 (7.9) 0.15 (7.7) 
IIV, interindividual variability; RSE, relative standard error; CL, total clearance; V1,central volume of distribution; V2, peripheral volume of 
distribution; Q, inter-compartmental clearance; NE, not estimated, VIH status: negative = 1, positive = 2 
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It was not possible to estimate population parameter variability on 
Q. The elimination half-life before covariate inclusionaveraged 13.9 
h (coefficient of variation, 28.6%).  
Their means (± standard deviation) for age, weight, height and body 
surface area were 38.7 ± 9.6 years, 72.5 ± 14.7 kg, 176.2 ± 5.53 cm 
and 1.88 ±0.19 m², respectively. The mean duration of surgery was 
1.8 h (0.83 to 4 h), and the mean duration of blood losses after the 
surgery was 48 h (24 to 96 h). Blood losses, during and after the 
surgery, averaged 295.8 mL (50 to 900 mL) and 1149.6 mL (320 to 
3560 mL), respectively. 
A two-compartment model with time-varying central volume of 







Fig. 1: It shows linear regression analysis between A) central 
volume of distribution (V1) and patient body weight; B) central 
volume of distribution (V1) and HIV status; C) peripheral 
volume of distribution (V2) and HIV status 
 
In forward inclusion, only the viral status was significant for V1 
The elimination half-life after covariate inclusion averaged 14.5 h 
(coefficient of variation, 21.5%). The ratios of the between-subject 
variance predictable from covariate (BSVP = 0.093) to the total 
population parameter variance obtained without covariate analysis 
(PPV = 0.312) indicate that 29.8% of the overall variability in V
when compared with the base model. Its inclusion in the model was 
justified by 10-point improvement of the objective function value. 
() Observed concentrations (DV) 
1
 
Fig. 2: It shows time evolution profiles of factor VIII in 24 patients 
undergoing orthopedic surgery. Lines are obtained from individual 
predicted concentrations connected point by point 
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Fig. 3: It shows the goodness-of-fit plots for the final model. (A) 
Observed concentrations (DV) versus individual model 
predicted concentrations (IPRED); (B) DVversus model 
predicted concentrations (PRED); (C) Weighted residuals 
(WRES) versus PRED. The solid lines in (A) and (B) represent 
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The goodness of fit has been evaluated by comparing the regression 
line estimated on the DV versus IPRED values (slope: 1.07, 95% 
confidence interval (C. I.): 0.999, 1.1; intercept: −0.07 IU mL-1
 
Fig. 4: It shows visual predictive check plot for the studied 
population. The middle line depicts the model predicted 
median. The other lines (above and below the median) present 
the 5
, 95% C. 
I.: −0.15, 0.008) to the reference line of slope = 1 and intercept = 0. 
No significant difference occurred. Most of the weighted residuals 
lay within 2 units of perfect agreement and were symmetrically 
distributed around the zero ordinate. By examining the PE values 
(IPRED vs DV), the MDPE was 1.09% (95% confidence interval: 
−0.96, 3.15) and the MDAPE was 7.6% (95% confidence interval: 6.3, 
8.9). The MDPE and MDAPE of the population predictions PRED 
were 4.4% and 19.8%, respectively. These values were in a typical 
range for pharmacokinetic models. The plot of PEs versus time 





The VPC plot confirms the adequacy of model predictions, showing 
no apparent deviations between model and data. About 98% of the 
data fit well within the 5th-95th percentiles band and the data were 
symmetrically distributed around the median. The final model was 
fitted repeatedly to 1000 bootstrap-resampled data sets. 
DISCUSSION 
The treatment of hemophilia with factor VIII is both effective and 
complex. The factor VIII concentration before the beginning of the 
perfusion was performed to know basal concentration. Then 
concentrations were determined during and after the surgery to 
adapt the rate of perfusion. So, many factor VIII concentrations were 
available for this retrospective study. Pharmacokinetic data may be 
fundamental to maximize efficacy and to minimize cost of this 
treatment. A recent joint report from the World Health Organization 
(WHO), World Federation of Hemophilia and International Society of 
Thrombosis and Haemostasis states that the use of coagulation 
products should be optimized and that pharmacokinetics is 
fundamental to dosing [41]. Factors affecting pharmacokinetic 
outcomes include inter- and intra-patient variability, the type of 
factor VIII formulation administered to the patients and also the 
analytical method used to quantify the compound. 
In previous papers, either a one- [11-13,32] or a two-compartment 
model [27,28,30,31, 33,34] was used to describe factor VIII 
pharmacokinetics in human. This study is, to our knowledge, the 
first report of a population pharmacokinetic study of factor VIII 
carried out in patients during and after surgery. The two-
compartment model taking into account blood losses during and 
after surgery was the best model adapting to experimental points. 
We choose to record blood losses manually because this method 
allows differentiating surgical and post surgical periods. Blood loss 
being not linear during and after surgery, we cannot use, in our 
model, the Brecher method which estimates the total losses. 
Table 2: It shows bootstrap validation of the estimated population pharmacokinetic parameters in the final model 
 Original data 1000 Bootstrap replicates 
Parameters Mean estimate Median 2.5% quantile 
97.5% quantile 
V1 = θ1 x VIH status+θ θ7 1 = 3020 
θ1
θ
 = −1940 
1 = 3006 
θ1
1340-4376 
−4230-1270  = −1706 
CL = θ2 (mL h-1 θ) 1 229  = 220 195-246 
V2 = θ3 θ (mL) 1 2212  = 2600 872-3776 
Q = θ4 (mL h-1 θ) 1 601  = 618 343-1072 
θ θ5 1 1281  = 1560 38.1-3141 
θ θ6 1 1647  = 1740 709-3362 
Inter-individual variability 
ω² 0.219 V1 0.215 0.001-0.72 
ω² 0.0942 CL 0.0834 0.035-0.17 
ω² 0.484 V2 0.541 0.025-1.25 
ω² NE Q 
Residual variability, σ² 0.15 0.15 0.12-0.17 
CL, total clearance; V1,central volume of distribution; V2
 
, peripheral volume of distribution; Q, inter-compartmental clearance; NE, not estimated, 
These results indicated the reliability and robustness of the estimated parameters and thus the population pharmacokinetic model was acceptable. 
The number of patients (24)may seem not enough for population 
analysis, considering the clinical complexity of the patients. 
However, the pharmacokinetic parameters estimated using the 
bootstrap replicates are close to those obtained from the original 
data indicating that the model is acceptable. As previously reported, 
we found marked variation in pharmacokinetic parameters. In our 
population, the mean CL was 3.3 mL/ h/kg, mean Vss was 66.5 
mL/kg and mean t1/2 elimination was 14.5 h. Similar 
pharmacokinetic parameters were reported in the literature 
[4,12,14-22,28,29,30, 33,34]. In these published studies, significant 
relationships between body weight, age and total clearance, and 
between body weight and the volume of distribution have been 
reported. Recently, Karafoulidou et al [33] showed that HIV status 
was a significant categorical predictor for V1. In our study, a 
relationship was found between V1 and weight (P = 0.0263) and 
between V2 and weight (P = 0.0362) but they were not retained in 
the final model. Indeed, in forward inclusion, weight was not 
significant for both V1 and V2 when compared with the base model. 
As reported by Karafoulidou et al., we found that the central volume 
of distribution increased in HIV+ patients. The HIV covariate 
accounted for 29.8% of the unexplained variation across patients for 
V1. V1 increased by 33.3% (from 3550 mL to 4732 mL) in HIV+ 
patients compared to HIV- patients. This increase explained the need 
for higher doses in these patients. Indeed, the total administered 
dose increased by 26% in HIV+ patients (796 IU/kg) in regard to the 
other patients (632 IU/kg). Changes in the body mass / body fat 
ratio or possible distribution of the drug outside the blood volume 
due to the disease or endothelial inflammation following highly 
active antiretroviral therapy has been proposed to explain this 
increase [33,42]. Patients with haemophilia may also present other 
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clinical and pathological factor such as hepatitis C or liver cirrhosis. 
Too much data was missing, because of the retrospective nature of 
the study, to allow testing of these covariates in the model. Patients 
of this study received repeated continuous infusion of factor VIII, 
88% of concentrations were in the range 0.75-1.5 IU/mL. These 
concentrations were near to those reported by Hay et al [43]. 
CONCLUSION 
For the first time, clinicians could determine individual factor VIII 
pharmacokinetic parameters in taking into account blood loss. 
Stable concentrations over time can be of good efficacy and 
tolerance and decrease the infusion of concentrated red blood cells. 
This study may reduce the number of nursing procedures, optimize 
the amount of factor VIII used and thus reduce the cost of surgery. 
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